You are here

Tecentriq

Roche's Tecentriq is the first I-O drug to claim a post-surgery win in lung cancer. But will doctors use it?

Roche's Tecentriq is the first I-O drug to claim a post-surgery win in lung cancer. But will doctors use it?

Fierce Pharma

non-small cell lung cancer

Flag link:

Roche joins the FDA accelerated approval revamp team, nixing a Tecentriq bladder cancer nod

Roche joins the FDA accelerated approval revamp team, nixing a Tecentriq bladder cancer nod

Fierce Pharma

Flag link:

Roche gets FDA breakthrough therapy status for tiragolumab plus Tecentriq

Roche gets FDA breakthrough therapy status for tiragolumab plus Tecentriq

Pharmaceutical Business Review

non-small cell lung cancer

breakthrough therapies

Flag link:

Merck, Bristol Myers, AstraZeneca and Roche lose bid to expand PD-1/L1 reach in China

Merck, Bristol Myers, AstraZeneca and Roche lose bid to expand PD-1/L1 reach in China

Fierce Pharma

Bristol-Myers Squibb

PD-1 inhibitors

Flag link:

ESMO: Roche's mixed results put Tecentriq's triple-negative breast cancer use into question

ESMO: Roche's mixed results put Tecentriq's triple-negative breast cancer use into question

Fierce Pharma

triple negative breast cancer

Flag link:

FDA puts Roche's Tecentriq under the lens in breast cancer after recent trial flop

FDA puts Roche's Tecentriq under the lens in breast cancer after recent trial flop

Fierce Pharma

triple negative breast cancer

clinical trials

Flag link:

In surprising setback, combo of Roche’s Tecentriq and chemo fails to help patients with triple-negative breast cancer

In surprising setback, combo of Roche’s Tecentriq and chemo fails to help patients with triple-negative breast cancer

Endpoints

triple negative breast cancer

Flag link:

FDA approves Roche’s Tecentriq plus Cotellic and Zelboraf for people with advanced melanoma

FDA approves Roche’s Tecentriq plus Cotellic and Zelboraf for people with advanced melanoma

Pharmaceutical Business Review

Flag link:

Roche’s Tecentriq claims melanoma OK, but don’t expect a sales surge

Roche’s Tecentriq claims melanoma OK, but don’t expect a sales surge

Pharmaforum

Bristol-Myers Squibb

Flag link:

Genentech's Tecentriq-Avastin Combo Fails to Hit Primary Endpoint in Ovarian Cancer

Genentech's Tecentriq-Avastin Combo Fails to Hit Primary Endpoint in Ovarian Cancer

BioSpace

clinical trials

Flag link:

Exelixis initiates phase 3 trial of Cabozantinib/Atezolizumab combo in prostate cancer

Exelixis initiates phase 3 trial of Cabozantinib/Atezolizumab combo in prostate cancer

Pharmaceutical Business Review

metastatic castration-resistant prostate cancer

clinical trials

Flag link:

I-O blockbusters from Merck, BMS and more linked to poor COVID-19 outcomes: study

I-O blockbusters from Merck, BMS and more linked to poor COVID-19 outcomes: study

Fierce Pharma

immuno-oncology

checkpoint inhibitors

Bristol-Meyers Squibb

Flag link:

Roche's Checkpoint Inhibitor Hits the Mark in Early Triple-Negative Breast Cancer Study

Roche's Checkpoint Inhibitor Hits the Mark in Early Triple-Negative Breast Cancer Study

BioSpace

triple negative breast cancer

clinical trials

Flag link:

Roche nabs frontline OK for Avastin/Tecentriq in common liver cancer, besting an old Bayer drug

Roche nabs frontline OK for Avastin/Tecentriq in common liver cancer, besting an old Bayer drug

Endpoints

metastatic hepatocellular carcinoma

Flag link:

FDA approves Genentech’s Tecentriq as first-line monotherapy for certain people with metastatic NSCLC

FDA approves Genentech’s Tecentriq as first-line monotherapy for certain people with metastatic NSCLC

Pharmaceutical Business Review

metastatic non-small cell lung cancer

Flag link:

Roche’s TIGIT drug shows promise in untreated lung cancer

Roche’s TIGIT drug shows promise in untreated lung cancer

Pharmaforum

metastatic non-small cell lung cancer

Flag link:

AACR: Roche's Tecentriq, added to Cotellic and Zelboraf, stalls melanoma progression

AACR: Roche's Tecentriq, added to Cotellic and Zelboraf, stalls melanoma progression

Fierce Pharma

Flag link:

Kahr raises $18M to test CD47 drug with Roche's Tecentriq

Kahr raises $18M to test CD47 drug with Roche's Tecentriq

Fierce Biotech

Flag link:

FDA Grants Priority Review to Roche's Lung Cancer Drug Tecentriq

FDA Grants Priority Review to Roche's Lung Cancer Drug Tecentriq

Motley Fool

priority review

non-squamous non-small cell lung cancer

non-small cell lung cancer

Flag link:

Roche gets Chinese approval for Tecentriq plus chemotherapy to treat ES-SCLC

Roche gets Chinese approval for Tecentriq plus chemotherapy to treat ES-SCLC

Pharmaceutical Business Review

extensive-stage small cell lung cancer

Flag link:

Pages